Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENDU Vaccine in Prostate Cancer Relapse
NCT04701021Phase 1Completed
- Sponsor
- Ultimovacs ASA
- Start
- Feb 2021
- Primary completion
- Aug 2023
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Tendu in prostate cancer (PCa) (3 arms), sponsored by Ultimovacs ASA. Primary endpoint: Assessment of safety and tolerability of TENDU vaccine at 6 months. Started Feb 2021; status: completed.
02
Drugs
Tendu
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04701021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701021.